1. Antibacterial efficacy of cold atmospheric plasma against Enterococcus faecalis planktonic cultures and biofilms in vitro.
- Author
-
Theinkom F, Singer L, Cieplik F, Cantzler S, Weilemann H, Cantzler M, Hiller KA, Maisch T, and Zimmermann JL
- Subjects
- Biofilms growth & development, Cytoplasm drug effects, Cytoplasm metabolism, Dose-Response Relationship, Drug, Enterococcus faecalis cytology, Enterococcus faecalis growth & development, Intracellular Membranes drug effects, Intracellular Membranes metabolism, Anti-Bacterial Agents pharmacology, Biofilms drug effects, Enterococcus faecalis drug effects, Enterococcus faecalis physiology, Plankton microbiology, Plasma Gases pharmacology
- Abstract
Nosocomial infections have become a serious threat in our times and are getting more difficult to handle due to increasing development of resistances in bacteria. In this light, cold atmospheric plasma (CAP), which is known to effectively inactivate microorganisms, may be a promising alternative for application in the fields of dentistry and dermatology. CAPs are partly ionised gases, which operate at low temperature and are composed of electrons, ions, excited atoms and molecules, reactive oxygen and nitrogen species. In this study, the effect of CAP generated from ambient air was investigated against Enterococcus faecalis, grown on agar plates or as biofilms cultured for up to 72 h. CAP reduced the colony forming units (CFU) on agar plates by > 7 log10 steps. Treatment of 24 h old biofilms of E. faecalis resulted in CFU-reductions by ≥ 3 log10 steps after CAP treatment for 5 min and by ≥ 5 log10 steps after CAP treatment for 10 min. In biofilm experiments, chlorhexidine (CHX) and UVC radiation served as positive controls and were only slightly more effective than CAP. There was no damage of cytoplasmic membranes upon CAP treatment as shown by spectrometric measurements for release of nucleic acids. Thus, membrane damage seems not to be the primary mechanism of action for CAP towards E. faecalis. Overall, CAP showed pronounced antimicrobial efficacy against E. faecalis on agar plates as well as in biofilms similar to positive controls CHX or UVC., Competing Interests: The study employed a plasma source which had been developed and patented by terraplasma GmbH. The prime interest of terraplasma was to determine the safety of the plasma source in an independent study, carried out without undue influence by the company so that it provides a valuable documentation. The scientific value of this work lies in the possibility for advancing plasma treatment and providing the quantitative background for this future application, as well as paving the way for a clinical study. In this sense the interest is complementary – there is no competing interest. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2019
- Full Text
- View/download PDF